Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.47 -1.26 (-0.80%)
Official Closing Price Updated: 6:30 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Four Stocks To Watch This Week - Monday, July 22
It's possible that following the Crowdstrike/Microsoft outage last week, big investor over-reliance on the tech mega-caps could be under review in the medium term. 
Via Talk Markets
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate
Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epilepsy after Phase 2 data. 
Via Benzinga
Johnson & Johnson Faces Legal Hurdle In Talc Lawsuit Battle
Johnson & Johnson's attempt to disqualify Beasley Allen from representing plaintiffs in talc cancer cases is denied by a New Jersey judge, impacting the company's strategy to settle claims through... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Stocks See Mixed Reactions Amid Geopolitical Tensions And Earnings Surprises
Concerns were exacerbated by comments from former President Trump, raising fears of geopolitical tensions. 
Via Talk Markets
Topics Government
Exposures Political
Why the dividend investor may take a look at NYSE:JNJ.
Uncovering Dividend Opportunities with JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
This fund has a basket of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
MarketBeat Week in Review – 7/15 - 7/19
Stocks took a breather to close the week, but corporate earnings and the next reading on the PCE index will help determine what direction the market moves next 
Via MarketBeat
Topics Economy
Exposures Interest Rates
7 Consumer Staples Stocks to Buy at a 52-Week Low in July
If the long-awaited sector rotation is happening, it’s time to look at these undervalued consumer staples stocks. 
Via InvestorPlace
3 Blue-Chip Stocks to Buy for Christmas in July
Investors may be starting to rotate away from the tech sector, if so here are three blue-chip stocks to buy. 
Via InvestorPlace
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
3 Dividend Stocks That Demand Investor Attention
Explore and consider three heavyweight dividend stocks that offer strong yields and growth potential for savvy investors. 
Via InvestorPlace
These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results
Via Benzinga
3 Blue-Chip Stocks to Buy If the Dow Crashes
Blue-chip stocks provide the ballast to keep a portfolio steady when markets go south as they offer reliable long-term returns. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Microsoft To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
A Top-Tier Dividend Stock Every Passive-Income Investor Should Consider
This healthcare behemoth is one of the best dividend stocks on the planet. 
Via The Motley Fool
Wall Street Gearing Up For Tech-Led Rebound Ahead Of Netflix Earnings: Economist Expects Soft Landing But Says Brace For Bigger Fed Rate Cuts If This Happens
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly repo 
Via Benzinga
Topics Economy
Exposures Interest Rates
Is Johnson & Johnson a Buy Now?
Second-quarter results suggest the spinoff of the company's slow-growing consumer goods segment is having the intended effect. 
Via The Motley Fool
2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold Forever
The market can be unpredictable in the short run, but over the long term, the best companies will build lasting wealth for their shareholders. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Johnson & Johnson Stock Was a Winner on Wednesday
The company did a fine job of boosting sales of numerous drugs. 
Via The Motley Fool
Stock Of The Day: Johnson & Johnson Hits Crucial Roadblock — Can It Break Through?
The chart of Johnson & Johnson shows a clear illustration of an important market dynamic. Certain price levels that are more important than others. 
Via Benzinga
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
JNJ earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq 100 Suffers Worst Day In 11 Months As Chipmakers Tumble On China Curbs; Magnificent 7 Wipe Out $500B : What's Driving Markets Wednesday?
It’s deep red on Wall Street on Wednesday, with tech stocks sharply falling amid a semiconductor broad-based selloff following news that the Biden administration is hastening export restrictions to... 
Via Benzinga
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Exposures COVID-19
Johnson And Johnson Continues To Focus On Medical Innovation
On Wednesday, Johnson & Johnson (NYSE: JNJ) reported its second quarter results that reflected a strong momentum of its medtech and innovative medicine divisions. 
Via Benzinga
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum
Johnson & Johnson reported a solid quarter for Q2 but issued mixed guidance. The critical detail is that sequential growth continues, and YOY growth is on tap. 
Via MarketBeat
Exposures COVID-19
JNJ Q2 2024 Sales Surge To $22.4 Billion, Beating Expectations
Johnson & Johnson reported a 4.3% increase in sales to $22.4 billion in Q2 2024, with operational growth at 6.6% and adjusted EPS rising by 10.2% to $2.82. 
Via Talk Markets
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
Via Benzinga
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
Johnson & Johnson's Q2 earnings report shows a 10.2% rise in adjusted EPS to $2.82 and a 4.3% increase in sales to $22.45 billion, surpassing expectations. The company highlights strong performance in... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.